N6-[(苯基甲氧基)羰基]-D-赖氨酸苄酯单盐酸盐 | 156917-23-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N6-[(苯基甲氧基)羰基]-D-赖氨酸苄酯单盐酸盐
• 英文名称: N⁶-benzyloxycarbonyl-D-lysine benzyl ester; hydrochloride
• 英文别名: N⁶-Benzyloxycarbonyl-D-lysin-benzylester; Hydrochlorid；H-D-Lys(Z)-Obzl HCl；benzyl (2R)-2-amino-6-(phenylmethoxycarbonylamino)hexanoate;hydrochloride
• CAS: 156917-23-6
• 化学式: C₂₁H₂₆N₂O₄*ClH
• mdl: MFCD00065241
• 分子量: 406.909
• InChiKey: XHBTZNKKLKICJY-FSRHSHDFSA-N

物化性质

• 熔点：
  139 °C

计算性质

• 辛醇/水分配系数(LogP)：
  3.32
• 重原子数：
  28
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  90.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N6-[(苯基甲氧基)羰基]-D-赖氨酸苄酯单盐酸盐 、 N,N'-bis(N-(carboxymethyl))-N,N'-bis(N-(2-(4-fluorophenyl)ethyl)carboxamidomethyl)benzene-1,3-dicarboxamide 在 N,N-二异丙基乙胺 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以99%的产率得到benzyl (2S)-2-[[2-[[2-[2-(4-fluorophenyl)ethylamino]-2-oxoethyl]-[3-[[2-[2-(4-fluorophenyl)ethylamino]-2-oxoethyl]-[2-oxo-2-[[(2S)-1-oxo-1-phenylmethoxy-6-(phenylmethoxycarbonylamino)hexan-2-yl]amino]ethyl]carbamoyl]benzoyl]amino]acetyl]amino]-6-(phenylmethoxycarbonylamino)hexanoate
  参考文献：
  名称：

  Higher order iminodiacetic acid libraries for probing protein–protein interactions

  摘要：

  Full details of the preparation of iminodiacetic acid diamide dimer (2040 compounds), trimer (560 compounds), and tetramer (1596 compounds) libraries by multistep convergent solution-phase synthesis for studying protein-protein interactions are provided. The libraries were assembled in a format providing small 8-10 compound mixtures and the deconvolution of many of the small mixtures to identify screening leads by resynthesis of the individual components have been conducted for 320 of the individual compounds to date. A representative example of the subsequent exploration of the structure-activity relationships for an identified receptor binding antagonist (200 additional individual compounds) and steps taken for potential elaboration to a receptor dimerization agonist are defined with preparation of representative linked dimers (70 compounds). (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(98)00128-x

文献信息

• NOVEL AZAPEPTIDE OR AZAPEPTIDOMIMETIC COMPOUNDS INHIBITING BCRP AND/OR P-GP
  申请人：Paris Joelle

  公开号：US20120010161A1

  公开（公告）日：2012-01-12

  The present invention relates to compounds of azapeptide or azapeptidomimetic type of formula (I): in which R 1 , R 2 , R 3 , X 1 , X 2 , X 3 , X 4 and Y are as defined in claim 1, to pharmaceutical compositions containing them and to such compounds as adjuvant for an anticancer or anti-infectious medicament.

  本发明涉及式(I)的氮杂肽或氮杂肽类似物化合物，其中R1、R2、R3、X1、X2、X3、X4和Y如权利要求1所定义，以及含有它们的药物组合物，以及作为抗癌或抗感染药物的辅助剂的这种化合物。
• PENICILLIN-BINDING PROTEIN INHIBITORS
  申请人：Venatorx Pharmaceuticals, Inc.

  公开号：EP3630783A1

  公开（公告）日：2020-04-08
• [EN] PENICILLIN-BINDING PROTEIN INHIBITORS<br/>[FR] INHIBITEURS PROTÉIQUES DE LIAISON À LA PÉNICILLINE
  申请人：VENATORX PHARMACEUTICALS INC

  公开号：WO2018218154A1

  公开（公告）日：2018-11-29

  Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
• Higher order iminodiacetic acid libraries for probing protein–protein interactions
  作者：Dale L. Boger、Joel Goldberg、Weiqin Jiang、Wenying Chai、Pierre Ducray、Jae Kyoo Lee、Rachel S. Ozer、Carl-Magnus Andersson

  DOI：10.1016/s0968-0896(98)00128-x

  日期：1998.8

  Full details of the preparation of iminodiacetic acid diamide dimer (2040 compounds), trimer (560 compounds), and tetramer (1596 compounds) libraries by multistep convergent solution-phase synthesis for studying protein-protein interactions are provided. The libraries were assembled in a format providing small 8-10 compound mixtures and the deconvolution of many of the small mixtures to identify screening leads by resynthesis of the individual components have been conducted for 320 of the individual compounds to date. A representative example of the subsequent exploration of the structure-activity relationships for an identified receptor binding antagonist (200 additional individual compounds) and steps taken for potential elaboration to a receptor dimerization agonist are defined with preparation of representative linked dimers (70 compounds). (C) 1998 Elsevier Science Ltd. All rights reserved.